Dr. Bosse on the Safety Profile With Radium-223 Plus VEGF in RCC

Dominick Bosse, MD, fellow, Dana-Farber Cancer Institute, discusses the safety profile demonstrated with the combination of radium-223 and VEGF-targeted therapy for patients with renal cell carcinoma (RCC).

Dominick Bosse, MD, fellow, Dana-Farber Cancer Institute, discusses the safety profile demonstrated with the combination of radium-223 dichloride (Xofigo) and VEGF-targeted therapy for patients with renal cell carcinoma (RCC).

The combination of radium-223 and VEGF-targeted agents is feasible and safe. There was no dose limiting toxicity with the combination. There is a particular interest in investigating hematologic toxicity because radium-223 can affect bone marrow, says Bosse.

The toxicity profile is reassuring and overlaps what is known with VEGF targeted therapy, states Bosse. There was only one event of grade 3 anemia, which was not unexpected in the RCC population.

Related Videos
Guillermo Garcia-Manero, MD
Amer Zeidan, MBBS
Michael K. Gibson MD, PhD
Colin E. Champ, MD
Shilpa Gupta, MD
Samer A. Srour, MB ChB, MS
Adam D. Cohen, MD, director, Myeloma Immunotherapy, associate professor in medicine, hematology/oncology, Abramson Cancer Center, University of Pennsylvania
Alexandra Sokolova, MD
Christie J. Hilton, DO
Yuan Yuan, MD, PhD
Related Content